PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Current prostate cancer (PCa) risk stratification methods are often inadequate for predicting disease progression and patient outcomes.
• Telomere maintenance is a critical hallmark of cancer, with PCa cells exclusively utilizing telomerase for this process.
• TERT, the catalytic component of telomerase, is not a suitable prognostic marker in PCa due to low expression levels.

Purpose of the Study:

• To identify novel prognostic markers for prostate cancer by investigating transcription factors that regulate TERT expression.
• To evaluate the potential of PITX1 as a prognostic marker in PCa.

Main Methods:

• Development and application of a novel gene regulatory modeling strategy.
• Analysis of a comprehensive transcriptome dataset from 445 primary PCa samples.
• Functional assays, chromatin immunoprecipitation, and clinical data analysis of over 15,000 PCa samples.

Main Results:

• Six transcription factors were predicted as TERT regulators, with PITX1 identified as a prominent factor.
• PITX1 expression positively correlated with telomere staining intensity and activated TERT expression in PCa cells.
• High PITX1 expression in PCa tumors was associated with increased Ki67 expression, worse prognosis, and longer telomere length.

Conclusions:

• PITX1 serves as an excellent prognostic marker for prostate cancer.
• PITX1's role in activating TERT expression highlights its significance in PCa telomere maintenance and progression.
• The findings offer a new avenue for improving risk stratification and understanding PCa development.